Precision Business Insights
Portfolio

 

Research Reports

RNA Vaccines Pipeline Analysis Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

RNA Vaccines Pipeline Analysis Market: Global By Clinical Trial Phase (Pre-clinical Phase, Phase-I, Phase-II, Phase-III), By Application (Cancer, Renal Disorders, Cardiovascular Disorders, Metabolic Disorders, Infectious Diseases, Others), and Geography

 

Global RNA Vaccines Pipeline Analysis Report Description:

Global RNA vaccines pipeline analysis report gives comprehensive outlook on RNA vaccines across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global RNA vaccines market gives future market sizes (US$ Mn) on the basis of clinical trial phase, application, and region. This report studies global RNA vaccines dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global RNA vaccines market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global RNA vaccines market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global RNA vaccines market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global RNA vaccines products.

Global RNA Vaccines Pipeline Analysis:

The global RNA Vaccines market estimated to be valued US$ XX Mn in 2018 and poised to grow at significant CAGR over 2019-2025 due to increase in prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in number of biopharmaceutical and biotechnology industries,  rise in funding for the development of RNA vaccines from public and private sectors, promising pipeline drugs, and wide range of applications with RNA vaccines are the major factors that are driving the growth of the global RNA vaccines market over the forecast timeframe.

Increase in the Prevalence of Cancer and Other Chronic Diseases

Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA vaccines market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi vaccines, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA vaccines market over the forecast years.

North America Accounts for Larger Market Revenue Share in Global RNA Vaccines Pipeline Analysis

North America accounted for larger revenue share in global RNA vaccines market with significant CAGR. Increase in prevalence of cancer, cardiovascular, and other chronic diseases in U.S. and Canada, rise in R&D activities for the development of RNA vaccines, and promising pipeline products and product approval by FDA are anticipated to propel the market. Europe RNA vaccines market projected to grow at significant rate owing to increase in research and development on newer RNA vaccines in the market for chronic diseases, increase in number of biopharmaceutical and biotechnology industries, and increase in healthcare expenditure are expected to enhance the market.

Competition Assessment

Key player’s profiles in the global RNA vaccines market include:

  • Moderna, Inc.
  • CureVac AG
  • BioNTech AG
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • miRagen Vaccines, Inc.
  • GeneOne Life Science

Global contrast media agents market is surging owing to strong pipeline products, collaborations, and acquisitions by the market players. For instance, In October 2018, CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA-based intramuscular rabies vaccine. In September 2018, GeneOne Life Science entered into an exclusive license with the Houston Methodist Research Institute to produce RNA vaccines and therapeutics

Key Findings of the Report:

 

  • Global RNA vaccines market expanding at significant CAGR over 2019 to 2025 owing to increase in the prevalence of cancer and other chronic diseases
  • Based on application, cancer segment accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global RNA vaccines market

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

Detailed Segmentation

 

By Clinical Trial Phase

  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III

By Application

  • Cancer
  • Renal Disorders
  • Cardiovascular Disorders
  • Metabolic Disorders
  • Infectious Diseases
  • Others

Geography

 

  • North America
  • U S
  • Canada
  • Europe
  • Germany
  • France
  • U K
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America
  • Middle East and Africa (MEA)
  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 

 

Table of Content

  1. Executive Summary
  2. Global RNA Vaccines Pipeline Analysis Introduction
    • Global RNA Vaccines Pipeline Analysis – Taxonomy
    • Global RNA Vaccines Pipeline Analysis –Definitions
      • Clinical Trial Phase
      • Application
  1. Global RNA Vaccines Pipeline Analysis Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global RNA Vaccines Pipeline Analysis Dynamic Factors – Impact Analysis
    • Global RNA Vaccines Pipeline Analysis – Competition Landscape
  2. Global RNA Vaccines Pipeline Analysis, 2014 – 2018 and Forecast, 2019 – 2025
    • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Global RNA Vaccines Pipeline Analysis, By Clinical Trial Phase, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Pre-Clinical Phase
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase-I
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase-II
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase-III
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global RNA Vaccines Pipeline Analysis Forecast, By Application, 2014 – 2018 and Forecast, 2019 – 2025
    • Cancer
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Renal Disorders
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cardiovascular Disorders
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Metabolic Disorders
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Infectious Diseases
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global RNA Vaccines Pipeline Analysis Forecast, By Region, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global RNA Vaccines Pipeline Analysis – Opportunity Analysis Index, By Clinical Trial Phase, Application, and Region, 2019 – 2025
  2. North America RNA Vaccines Pipeline Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America RNA Vaccines Pipeline Analysis – Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2019 – 2025
    • North America RNA Vaccines Pipeline Analysis Dynamics – Trends
  3. Europe RNA Vaccines Pipeline Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe RNA Vaccines Pipeline Analysis – Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2019 – 2025
    • Europe RNA Vaccines Pipeline Analysis Dynamics – Trends
  4. Asia-Pacific RNA Vaccines Pipeline Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific RNA Vaccines Pipeline Analysis – Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2019 – 2025
    • Asia-Pacific RNA Vaccines Pipeline Analysis Dynamics – Trends
  5. Latin America RNA Vaccines Pipeline Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America RNA Vaccines Pipeline Analysis – Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2019 – 2025
    • Latin America RNA Vaccines Pipeline Analysis Dynamics – Trends
  6. Middle East and Africa RNA Vaccines Pipeline Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA RNA Vaccines Pipeline Analysis – Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2019 – 2025
    • MEA RNA Vaccines Pipeline Analysis Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Clinical Trial Phase & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Moderna, Inc.
      • CureVac AG
      • BioNTech AG
      • Alnylam Pharmaceuticals, Inc.
      • Arbutus Biopharma Corporation
      • miRagen Therapeutics, Inc
      • GeneOne Life Sciences
  1. Research Methodology
  2. Key Assumptions and Acronyms

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials

Contact SalesTOLL FREE: +1-866-598-1553